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Abstract
Background Surgical site infections (SSI) continue to be
a significant source of morbidity despite the introduction of
perioperative intravenous antibiotics. Our objective was to
assess the efficacy of local vancomycin powder on lower-
ing deep SSI rates in high-energy tibial plateau and pilon
fractures.
Materials and methods A retrospective review of all
tibial plateau and pilon fractures treated in 2012 at our
level I trauma center identified 222 patients. Of these, 107
patients sustained high-energy injuries that required staged
fixation, and 93 had minimum 6 month follow-up. Ten
patients received 1 gram vancomycin powder directly into
the surgical wound at the time of definitive fixation, and the
remaining 83 patients served as controls. SSI was defined
according to criteria from the Centers for Disease Control.
Demographic data, patient comorbidities, injury and
treatment details, and infection details were recorded.
Descriptive and comparative statistics were performed.
Results Amongst the vancomycin powder group, 1 pa-
tient (10 %) developed a deep SSI; in the control group, 14
(16.7 %) developed deep SSI. The rate of deep SSI be-
tween the groups was not statistically significantly different
(P = 1.0). The groups were statistically similar with regard
to injuries, treatment, comorbidities, and infectious out-
comes (P values range = 0.06–1.0).
Conclusions The application of local vancomycin powder
into surgical wounds of high-energy tibial plateau and pilon
fractures did not reduce the rate of deep SSI in this retro-
spective review. There is a need to find effective, cheap, and
widely available methods for prevention of SSI. Basic sci-
ence and larger prospective clinical studies are needed to
further delineate the role of local vancomycin powder as a
modality to reduce deep SSI in extremity trauma.
Level of evidence Level III, therapeutic.
Keywords Tibial plateau  Tibial plafond  Pilon 
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Introduction
Infection is a well-known complication of operative fixa-
tion of extremity fractures. Such infections have a sig-
nificant effect on patients and often require repeat surgery,
prolonged systemic antibiotic use and lead to delay in
fracture healing and rehabilitation. The risk of mortality
doubles in a patient with a surgical site infection (SSI) and
the cost of care increases significantly [1]. Risk factors for
post-traumatic infection include open fractures, smoking,
alcoholism, sustained intensive care unit stay, inadequate
debridement at the fracture site and malnutrition [2, 3]. In a
patient sustaining high-energy trauma, immune system
dysfunction results, as evidenced by decreased ability of
polymorphonuclear leukocytes (PMNs) in chemotaxis,
decreased superoxide formation and decreased microbial
elimination [4]. In the setting of fractures, bone that is
devoid of periosteum and other surrounding devitalized
tissue serve as an ideal medium for bacterial colonization
and replication. Introduction of hardware to appropriately
manage a fracture becomes yet another suitable medium
for bacterial proliferation given that most metals are elec-
trochemically active and promote molecular adhesion [5].
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Some authors have reported infection rates of 14–60 % in
high-energy lower extremity fractures [6–11]. Systemic an-
tibiotics reduce surgical site infections, but they are limited
by the risk of toxicity. Additionally, traumatic tissues have a
compromised blood supply, further limiting the effective-
ness of systemic antibiotics. Local antibiotics avert this by
sterilizing the wound and preventing the development of a
biofilm. The development of a complex glycocalyx biofilm
around bacterial colonies greatly impedes the delivery of
systemic antibacterial agents and allows bacteria to become
more virulent than in their non-adherent state [12, 13].
Administration of perioperative, intravenous antibiotics
prior to making a surgical incision has become standard of
care and has been effective at reducing surgical infections
[14, 15]. Vancomycin is a glycopeptide that inhibits bac-
terial cell wall synthesis and is used mostly in the pro-
phylaxis and treatment of Gram-positive bacteria. Topical
vancomycin offers advantages over systemic administra-
tion because higher local concentrations can be achieved
and directed to the site of need. Additionally, organisms
that may be otherwise resistant to a given systemic
therapeutic concentration may be sensitive to the local
concentrations [16]. Local antibiotics are commonly de-
livered via cement beads and spacers. However, these are
not always practical, as they require space for placement
and necessitate late removal.
Topical vancomycin powder has become popular over
the last decade as its efficacy in spine surgery has been
demonstrated. A meta-analysis pooling 5888 spine patients
that evaluated the effectiveness of topical vancomycin
powder at preventing SSI and deep incisional infections
showed a significant protective effect of vancomycin
powder [17]. Despite extensive research into vancomycin
powder efficacy in the spine literature and some work in
the field of vascular surgery, no literature exists on van-
comycin powder use in prevention of surgical wound in-
fection in extremity injuries.
The objective of our retrospective review was to assess
the efficacy of intraoperative vancomycin powder admin-
istration on preventing deep SSI in high-energy lower ex-
tremity trauma of the tibial plateau and pilon. We
hypothesized that the use of intrawound vancomycin
powder would reduce the incidence of deep SSI in the
treatment group as compared to well-matched controls.
Materials and methods
Inclusion/exclusion criteria, treatment, and data
collection
The study protocol was approved by the institutional re-
view board at the participating level I trauma center.
Inclusion criteria consisted of patients older than 18 years
of age who had undergone staged operative fixation of their
high-energy tibial plateau or pilon injury. Staged treatment
(external fixation, limited internal fixation, or splinting)
was defined as definitive internal fixation at a minimum of
5 days post-injury after swelling had resolved. Exclusion
criteria consisted of patients with follow-up less than
6 months.
A total of 222 adult patients were found in the institu-
tional database to have sustained tibial plateau and pilon
fractures between 1 January 2012 and 31 December 2012.
Of these injuries, 50 were treated non-operatively, and 65
did not require staged fixation. The remainder of these
injuries (n = 107) were treated by the six board-certified
orthopaedic trauma surgeons at our institution. Of the 107
patients, 14 had a follow-up time of less than 6 months,
leaving 93 patients in the final analysis group. Charts and
operative reports of all injuries were reviewed, and ten
patients (10.8 %) were documented to have received
1 gram vancomycin powder (Hospira, Lake Forest, IL)
directly into the surgical wound at time of definitive fixa-
tion at the discretion of the treating surgeon. The remaining
83 patients served as the control group.
All patients received standard systemic antibiotic pro-
phylaxis consisting of 1 g IV cefazolin within 1 h of sur-
gical incision, followed by 1 g IV cefazolin every 8 h for
24 h postoperatively. If the patient was allergic to peni-
cillin, 900 mg IV clindamycin was used instead. Patient
demographics (age and gender), injury type (location, open
versus closed), smoking status, presence of diabetes, staged
treatment with external fixation, presence of single or dual
incision, presence of concomitant compartment syndrome
and time (in days) from presentation to definitive surgery
were all recorded. All patients records were evaluated for
signs of SSI for a minimum of 6 months post-operatively.
A deep SSI was defined as one requiring operative irriga-
tion and debridement. Wound site erythema without the
presence of fluctuance, drainage or purulence was defined
as a superficial SSI. Amongst the deep SSI patients, intra-
operative microbiological data was also collected.
Statistics
Using SPSS 22.0 software, dichotomous data was com-
pared using Fisher’s exact tests, while independent t tests
and Mann–Whitney U tests were used for comparisons of
parametric and non-parametric data, respectively. Statisti-
cal significance was set at P\ 0.05.
Outcome measure
The primary outcome measure was the occurrence of deep
SSI.
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Results
Demographic parameters did not differ statistically be-
tween the two groups. The average age of the vancomycin-
treated group was 55 years (range 38–73 years), and the
control age was 46 years (range 17–82 years), P = 0.064.
Of the 10 vancomycin-treated patients, 6 were male (60 %)
and 4 were female (40 %), and of the 83 control patients,
55 (54 %) were male and 38 (46 %) were female
(P = 1.0). Thirty-six (43 %) out of the 83 control subjects
were smokers and 2 (20 %) of the vancomycin-treated
were smokers (P = 0.191). Six (7 %) of the 83 control
patients were diabetic whereas no patient in the van-
comycin-treated group had diabetes (p = 1.0). Of the ten
vancomycin-treated patients, five (50 %) sustained a tibial
plateau injury and five (50 %) sustained a tibial plafond
(pilon) injury. Forty-six injuries in the control group were
pilon injuries and 37 were plateau injuries. Comparison of
injury type amongst the two groups was not statistically
significant (P = 0.751). A total of 3 injuries (30 %), all
pilon, were open injuries in the vancomycin-treated group,
and 23 (28 %) injuries were open in the control group
(P = 1.0). Patient characteristics and outcomes for the
treatment and control groups are presented in Table 1.
Amongst the vancomycin-treated group, one patient
(10 %) developed a deep SSI. In the control group of 83
patients, 14 patients (16.8 %) developed deep SSI. The rate
of deep SSI was not statistically different between the two
groups (P = 1.0). Seven (50 %) of the 14 patients in the
control group that developed a deep SSI initially had an
open injury. The one patient with a deep infection in the
vancomycin-treated group had an injury that was initially
open. There were no cases of superficial SSI in the van-
comycin-treated group and 7 cases (8 %) of superficial SSI
in the control group of 83 patients. The rate of superficial
SSI was not statistically different between the two groups
(P = 1.0). Seven (8 %) of the 83 control patients and one
(10 %) of the ten vancomycin-treated patients had con-
comitant compartment syndrome requiring surgical release.
The incidence of compartment syndrome was not statisti-
cally significant amongst the two groups (P = 1.0).
There was no significant difference in average time (in
days) to definitive surgical treatment amongst the two
groups (15.6 vs 19.8) for the control and vancomycin-
treated groups, respectively (P = 0.149). The groups were
statistically similar in terms of pre-operative temporizing
management with 74/83 (89 %) of control group and 9/10
(90 %) of the vancomycin-treated patients being externally
fixed prior to definitive management (P = 1.0). Thirty-four
(41 %) of the 83 control patients underwent dual-incision
operations at time of definitive fixation of their plateau and
pilons, and 59 % (49/83) had a single incision. In the
vancomycin-treated group, four out of ten (40 %) had
single incisions and 60 % had dual incisions. The number
of incisions did not differ statistically among the two
groups (P = 1.0).
In the vancomycin-treated group, the surgical site cul-
tures obtained from the one clinically infected patient at
time of surgical irrigation and debridement showed no
growth of pathogen at 6 months. Of the 14 infections in the
control group, 6 yielded Methicillin-sensitive Staphylo-
coccus aureus (MSSA), 4 resulted in Methicillin-resistant
Staphylococcus aureus (MRSA), 1 grew Staphylococcus
epidermidis, and 3 had no microbiology data available.
Table 1 Patient demographics,
injury, treatment characteristics
and rate of infection
Control Treatment P value
Total (n) 83 10
Average age (years) 46 55 0.06
Gender
M 45 6 1.00
F 38 4 1.00
Smoker n (%) 36 (43 %) 2 (20 %) 0.19
Diabetic n (%) 6 (7 %) 0 (0 %) 1.00
Pilon injuries n (%) 46 (55 %) 5 (50 %) 0.75
Plateau injuries n (%) 37 (45 %) 5 (50 %) 0.75
Open injuries n (%) 23 (28 %) 3 (30 %) 1.00
Staged treatment with external-fixation n (%) 74 (89 %) 9 (90 %) 1.00
Time to definitive fixation (days) 15.6 19.8 0.15
Single incision n (%) 34 (41 %) 4 (40 %) 1.00
Dual incision n (%) 49 (59 %) 6 (60 %) 1.00
Presence of compartment syndrome n (%) 7 (8 %) 1 (10 %) 1.00
Superficial infection n (%) 7 (8 %) 0 (0 %) 1.00
Deep infection n (%) 14 (16.8 %) 1 (10 %) 1.00
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One of the patients that grew MRSA concomitantly grew
Escherichia coli, and one patient with MSSA cultures also
grew Enterobacter aerogenes.
Discussion
Even with timely preoperative IV antibiotic prophylaxis,
meticulous attention to sterile technique, and less invasive
surgical procedures, postoperative infections continue to
occur in high-energy lower extremity fractures. Wound
infections can dramatically increase health care resource
utilization and further increase morbidity, especially in
patients with extremity trauma. The post-operative infec-
tion rates in the lower extremity are reported to be as high
as 60 % [6–11]. The objective of the present study was to
investigate the efficacy of vancomycin powder in the pre-
vention of deep SSI in high-energy lower extremity frac-
tures—something previously not studied.
We found no significant difference in the rate of deep or
superficial SSI high-energy tibia fractures when intra-
wound vancomycin powder was administered. There are
several possible unanswered questions with the use of local
vancomycin powder that necessitate more refined study.
The amount of local vancomycin necessary is unknown,
and it is possible that 1 g intra-wound vancomycin does not
achieve a therapeutic concentration, or does not do so for a
sufficient period of time. Perhaps in such a challenging
environment an antibiotic-eluting vehicle would be
beneficial such that prolonged local concentrations can be
maintained.
Pathogen resistance or targeting of inappropriate
pathogens may be another reason for antibiotic failure. No
cases of vancomycin resistance were seen in the infected
patients of the control group (n = 14), illustrating that
vancomycin resistance is not a significant issue in our re-
gion. Only one of the patients in the treatment group had an
infection, and cultures from the surgical site did not grow
any pathogens. It is difficult to surmise a connection be-
tween vancomycin administration and culture-negative
infection given the n = 1.
Our results are consistent with the work of Martin et al.
[19], who demonstrated no change in deep SSI in spinal
deformity cases (n = 305), and Mohammed et al. [20] who
showed no difference in SSI in the inguinal region after
vascular procedures (n = 424) with the administration of
intraoperative vancomycin. Martin et al. [19] mentions that
spinal deformity patients are at higher risk for infection due
to very large incisions, greater time of surgery, greater
blood loss, greater exposure to instruments and increased
amount of instrumentation. With regards to inefficacy of
vancomycin in inguinal wounds, the authors postulated that
the wound bed was not vascular enough for systemic
absorption of vancomycin, which could have helped
combat deep infections.
Several limitations of this study should be noted. The
small sample size limits the statistical power of our study
and the results must be interpreted with caution. The lack
of patient randomization could have led to surgeon bias and
treatment of the worst-appearing wounds with vancomycin,
falsely giving the impression of vancomycin inefficacy.
The incorporation of data from multiple surgeons also in-
troduces bias. Operative time, a factor known to contribute
to postoperative infections was not recorded. Additional
factors, such as limited mobility, malnutrition, and various
medical comorbidities, contribute to infection and were not
controlled for in this study as we were unable to reliably
obtain complete information due to the study’s retrospec-
tive nature.
With the high cost of managing the sequelae of SSI and
the growing emphasis of the health care system on reduc-
tion of readmissions, it is important to investigate methods
of reducing such complications. There is a need to find
effective, cheap, and widely available methods for pre-
vention of SSI. At a cost of approximately US $7 for 1 g
vancomycin powder, it is a low-cost measure that has
shown efficacy in lowering SSI rates for some surgeries,
and should be investigated further [18]. Our study provides
an initial look at vancomycin use in orthopaedic extremity
trauma and recommends the need for further study. Basic
science and larger prospective clinical studies are needed to
further delineate the role of local vancomycin powder as a
modality to reduce deep SSI in extremity trauma.
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